Who is sponsoring NCT04384380?

NCT04384380 is sponsored by Taoyuan General Hospital.

What drugs are being tested in NCT04384380?

Interventions in NCT04384380: Hydroxychloroquine Sulfate 200 MG [Plaquenil].

What condition does NCT04384380 study?

NCT04384380 studies Coronavirus Infection.

Is NCT04384380 still recruiting?

NCT04384380 is currently completed. Last updated 4 August 2020.

Last reviewed 2020-08-04 · How we verify

NCT04384380

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19

Completed NA Last updated 4 August 2020

What this trial tests

NA trial testing Hydroxychloroquine Sulfate 200 MG [Plaquenil] in Coronavirus Infection in 33 participants. Completed in 31 May 2020.

Timeline

1 April 2020

Primary endpoint
31 May 2020

31 May 2020

Quick facts

Lead sponsor	Taoyuan General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 April 2020
Primary completion	31 May 2020
Estimated completion	31 May 2020
Sites	1 location across Taiwan

Drugs / interventions tested

Hydroxychloroquine Sulfate 200 MG [Plaquenil] — full drug profile →

Conditions studied

Coronavirus Infection — all drugs for Coronavirus Infection →

Sponsor

Taoyuan General Hospital

Who can join

Adults 20 to 79, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effective medical treatment against COVID-19 infection is still unknown. Chloroquine phosphate is a well-known antimalarial drug which has been on the market for many years. Recently, in vitro study shown that Chloroquine is effective at both entry and at post-entry stages of the COVID-19 infection of Vero E6 cells with promising results. Chloroquine is also an immune-modifier and could distribute to the whole body including lung. Also, chloroquine is cheap and safe, and could be a promising agent against COVID-19 infection. However, only hydroxychloroquine (HCQ) with the extra hydroxyl group is available in Taiwan. Therefore, hydroxychloroquine instead become the best choice for the treatment candidate, since it shows higher in vitro potency (EC50) against COVID-19 with lower toxicity while retaining the original effect which compared with chloroquine.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, et al · · 2021 · cited 217× · PMID 33859192 · DOI 10.1038/s41467-021-22446-z
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Singh B, Ryan H, Kredo T, Chaplin M, et al · · 2021 · cited 140× · PMID 33624299 · DOI 10.1002/14651858.cd013587.pub2
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).
Chen CP, Lin YC, Chen TC, Tseng TY, et al · · 2020 · cited 67× · PMID 33264337 · DOI 10.1371/journal.pone.0242763
Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Izcovich A, Siemieniuk RA, Bartoszko JJ, Ge L, et al · · 2022 · cited 41× · PMID 35236729 · DOI 10.1136/bmjopen-2020-048502
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Abubakar AR, Sani IH, Godman B, Kumar S, et al · · 2020 · cited 39× · PMID 33402839 · DOI 10.2147/idr.s289037
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, et al · · 2020 · cited 29× · PMID 32623296 · DOI 10.1016/j.ctrv.2020.102063
Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.
Pal A, Pawar A, Goswami K, Sharma P, et al · · 2020 · cited 20× · PMID 32641874 · DOI 10.1007/s12291-020-00900-x
Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.
Eze P, Mezue KN, Nduka CU, Obianyo I, et al · · 2021 · cited 15× · PMID 33815925

Verify or expand the search:

Other trials of Hydroxychloroquine Sulfate 200 MG [Plaquenil]

Trials testing the same drug.

NCT04392128 — Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malign · Phase 2 · withdrawn

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

NCT04885504 — Post COVID-19 Biorepository · recruiting
NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting

Other Taoyuan General Hospital trials

Trials by the same sponsor.

NCT06679712 — Transbroncheal Novel PDT Peripheral Lung Tumor Ablation With 5-ALA · NA · not yet recruiting
NCT06784856 — Effects of AR-Based Education on PICC Care Knowledge, Clinical Reasoning, and Learning Engagement in Nurses · NA · completed
NCT05887505 — Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients · NA · not yet recruiting
NCT06095609 — The Implementation of Early Mobilization and Chest Physiotherapy on Weaning Rate of Prolong Weaning Patients. · NA · completed
NCT05311280 — The Effect of High Intensity Interval Exercise and Myofunctional Therapy on Obstructive Sleep Apnea · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04384380 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taoyuan General Hospital
Last refreshed: 4 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04384380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing